Analysis Orphazyme A S (OZYMF)
5/29/2024
Analysis of Orphazyme A S (OZYMF)
Orphazyme A/S (OZYMF) is showing a consistent price of 90.00 across multiple days. The Relative Strength Index (RSI) indicator is at 27.46, indicating the stock is oversold. The Moving Average Convergence Divergence (MACD) indicator is negative, with the MACD line below the signal line, suggesting a bearish trend.The Moving Average (MA) indicator aligns with the closing price at 90.00. The Simple Moving Average (SMA), Exponential Moving Average (EMA), and Weighted Moving Average (WMA) are all around 90.00, indicating stability in the stock price.
Overall, Orphazyme A/S seems to be trading in a tight range with bearish signals from the RSI and MACD indicators. Traders and investors may want to monitor the stock for a potential breakout or reversal in the near future.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The quarter before that, ending on January 31, 2025, had results released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company had an EPS estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong operating cash flow and levered free cash flow, with a positive profit margin and operating margin. The balance sheet shows a healthy current ratio, but a relatively high total debt to equity ratio. The company has a good return on assets and return on equity.
The stock statistics indicate a moderate short ratio and short percent of shares outstanding. The company has a significant percentage of shares held by institutions.
Valuation metrics show a relatively high PEG ratio and forward PE ratio. The company's market capitalization is substantial, with a high price to book ratio and price to sales ratio. The enterprise value to EBITDA and enterprise value to revenue ratios are also notable.
The stock price summary includes beta, moving averages, and the fifty-two week low and high prices. The dividends and splits information shows the dividend dates, split dates, dividend rates, and dividend yields for the company.
Income statement 💸
Here are the revenue figures for the company over the past four fiscal years:- 2020: $274,515,000,000
- 2021: $365,817,000,000
- 2022: $394,328,000,000
- 2023: $383,285,000,000
From these numbers, we can observe that the company experienced a steady increase in revenue from 2020 to 2022, reaching its peak in 2022. However, there was a slight decrease in revenue in 2023 compared to the previous year. This trend indicates a period of growth followed by a slight decline in revenue.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets fluctuate, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have been increasing steadily, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has been fluctuating, with the highest value in 2018 at $107,147,000,000.
Cash Flow 💶
This is a cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. Financing activities show significant changes, with fluctuations in common stock repurchases, debt issuances, and dividends.
5. Investing activities also vary, with notable amounts spent on acquisitions, investments, and capital expenditures.
6. The end cash position has been fluctuating, but generally, the company has maintained a healthy cash reserve.
7. Stock-based compensation has been a significant factor in the company's financial activities.
8. The company has engaged in both short-term and long-term debt activities to manage its financial position.
Earnings estimate
Based on analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average EPS estimate is $1.33, with a low estimate of $1.27 and a high estimate of $1.36. This shows growth compared to the EPS of $1.26 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average EPS estimate is $1.53, with a low estimate of $1.44 and a high estimate of $1.63. This indicates an increase from the EPS of $1.46 from the same quarter last year.
3. For the current fiscal year ending on September 30, 2024, the average EPS estimate is $6.59, with a low estimate of $6.43 and a high estimate of $6.92. This reflects growth compared to the EPS of $6.13 from the previous fiscal year.
4. Looking ahead to the next fiscal year ending on September 30, 2025, the average EPS estimate is $7.23, with a low estimate of $6.40 and a high estimate of $7.90. This suggests an increase from the EPS of $6.59 reported for the current fiscal year.
Overall, the analysts' estimates point towards a positive outlook for the company's earnings per share, showing growth in both quarterly and annual figures.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth expected in the next fiscal year compared to the current one.
Growth estimates
Based on the consensus estimates provided:- The current year growth rate is 7.5%
- The next quarter growth rate is 4.8%
- The current quarter growth rate is 5.6%
- The next year growth rate is 9.7%
- The next 5 years compound annual growth rate (CAGR) is 11%
- The past 5 years compound annual growth rate (CAGR) is 20.15%
It can be observed that the company is expected to experience a significant increase in growth rate compared to the past 5 years, with a particularly high growth rate projected for the next 5 years. This indicates positive expectations and potential for expansion in the company's performance.
Price target
Based on the analysts' forecast, the future price of the security is expected to range between $164 (low) and $250 (high), with a median estimate of $200 and an average estimate of $202.26. The current price of the security is $191.57.MACD of OZYMF
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
